Limits...
Corneal collagen cross-linking with hypoosmolar riboflavin solution in keratoconic corneas.

Gu S, Fan Z, Wang L, Tao X, Zhang Y, Mu G - Biomed Res Int (2014)

Bottom Line: After CXL, the thickness decreased to 410.3 ± 14.5 μm at the last follow-up.The mean CDVA was 0.54 ± 0.23 logarithm of the minimal angle of resolution before treatment and increased to 0.51 ± 0.21 logarithm at the last follow-up.The ECD was 2731.4 ± 191.8 cells/mm(2) before treatment and was 2733.4 ± 222.6 cells/mm(2) at 12 months after treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Shandong Provincial Hospital, Shandong University, No. 324, Jing 5 Road, Huaiyin District, Jinan, Shandong 250021, China.

ABSTRACT

Purpose: To report the 12-month outcomes of corneal collagen cross-linking (CXL) with a hypoosmolar riboflavin and ultraviolet-A (UVA) irradiation in thin corneas.

Methods: Eight eyes underwent CXL using a hypoosmolar riboflavin solution after epithelial removal. The corrected distance visual acuity (CDVA), manifest refraction, the mean thinnest corneal thickness (MTCT), and the endothelial cell density (ECD) were evaluated before and 6 and 12 months after CXL.

Results: The MTCT was 413.9 ± 12.4 μm before treatment and reduced to 381.1 ± 7.3 μm after the removal of the epithelium. After CXL, the thickness decreased to 410.3 ± 14.5 μm at the last follow-up. Before treatment, the mean K-value of the apex of the keratoconus corneas was 58.7 ± 3.5 diopters and slightly decreased (57.7 ± 4.9 diopters) at 12 months. The mean CDVA was 0.54 ± 0.23 logarithm of the minimal angle of resolution before treatment and increased to 0.51 ± 0.21 logarithm at the last follow-up. The ECD was 2731.4 ± 191.8 cells/mm(2) before treatment and was 2733.4 ± 222.6 cells/mm(2) at 12 months after treatment.

Conclusions: CXL with a hypoosmolar riboflavin in thin corneas seems to be a promising method for keratoconic eyes with the mean thinnest corneal thickness less than 400 μm without epithelium.

Show MeSH

Related in: MedlinePlus

Bar graph showing the mean best corrected visual acuity (BCVA) of patients before CXL and 6 months and 12 months after CXL with hypoosmolar riboflavin solution. logMAR: logarithm of the minimal angle of resolution.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4150415&req=5

fig3: Bar graph showing the mean best corrected visual acuity (BCVA) of patients before CXL and 6 months and 12 months after CXL with hypoosmolar riboflavin solution. logMAR: logarithm of the minimal angle of resolution.

Mentions: The mean CDVA at the time of the treatment was 0.54 ± 0.23 logarithm of the minimal angle of resolution and increased to 0.52 ± 0.13  (P = 1) at 6 months and 0.51 ± 0.21 (P = 0.285) at 12 months after treatment (Figure 3). The mean CDVA showed no significant change at these follow-up visits compared to pre-CXL values (all with P > 0.05). At the 12-month follow-up, 25% (2 of 8 eyes) gained at least 1 Snellen line and 62.5% (5 of 8 eyes) showed a stable CDVA.


Corneal collagen cross-linking with hypoosmolar riboflavin solution in keratoconic corneas.

Gu S, Fan Z, Wang L, Tao X, Zhang Y, Mu G - Biomed Res Int (2014)

Bar graph showing the mean best corrected visual acuity (BCVA) of patients before CXL and 6 months and 12 months after CXL with hypoosmolar riboflavin solution. logMAR: logarithm of the minimal angle of resolution.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4150415&req=5

fig3: Bar graph showing the mean best corrected visual acuity (BCVA) of patients before CXL and 6 months and 12 months after CXL with hypoosmolar riboflavin solution. logMAR: logarithm of the minimal angle of resolution.
Mentions: The mean CDVA at the time of the treatment was 0.54 ± 0.23 logarithm of the minimal angle of resolution and increased to 0.52 ± 0.13  (P = 1) at 6 months and 0.51 ± 0.21 (P = 0.285) at 12 months after treatment (Figure 3). The mean CDVA showed no significant change at these follow-up visits compared to pre-CXL values (all with P > 0.05). At the 12-month follow-up, 25% (2 of 8 eyes) gained at least 1 Snellen line and 62.5% (5 of 8 eyes) showed a stable CDVA.

Bottom Line: After CXL, the thickness decreased to 410.3 ± 14.5 μm at the last follow-up.The mean CDVA was 0.54 ± 0.23 logarithm of the minimal angle of resolution before treatment and increased to 0.51 ± 0.21 logarithm at the last follow-up.The ECD was 2731.4 ± 191.8 cells/mm(2) before treatment and was 2733.4 ± 222.6 cells/mm(2) at 12 months after treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Shandong Provincial Hospital, Shandong University, No. 324, Jing 5 Road, Huaiyin District, Jinan, Shandong 250021, China.

ABSTRACT

Purpose: To report the 12-month outcomes of corneal collagen cross-linking (CXL) with a hypoosmolar riboflavin and ultraviolet-A (UVA) irradiation in thin corneas.

Methods: Eight eyes underwent CXL using a hypoosmolar riboflavin solution after epithelial removal. The corrected distance visual acuity (CDVA), manifest refraction, the mean thinnest corneal thickness (MTCT), and the endothelial cell density (ECD) were evaluated before and 6 and 12 months after CXL.

Results: The MTCT was 413.9 ± 12.4 μm before treatment and reduced to 381.1 ± 7.3 μm after the removal of the epithelium. After CXL, the thickness decreased to 410.3 ± 14.5 μm at the last follow-up. Before treatment, the mean K-value of the apex of the keratoconus corneas was 58.7 ± 3.5 diopters and slightly decreased (57.7 ± 4.9 diopters) at 12 months. The mean CDVA was 0.54 ± 0.23 logarithm of the minimal angle of resolution before treatment and increased to 0.51 ± 0.21 logarithm at the last follow-up. The ECD was 2731.4 ± 191.8 cells/mm(2) before treatment and was 2733.4 ± 222.6 cells/mm(2) at 12 months after treatment.

Conclusions: CXL with a hypoosmolar riboflavin in thin corneas seems to be a promising method for keratoconic eyes with the mean thinnest corneal thickness less than 400 μm without epithelium.

Show MeSH
Related in: MedlinePlus